Hurvitz, S. A., Curigliano, G., André, F., Layman, R. M., Wesolowski, R., Cristofanilli, M., Martín, M., Ring, A. E., Puig, J. M., Richardet, M. E., Shin, J., Kim, S., Liu, L., Rosselli, G., Mutka, S., Cacovean, A., Suzuki, S., Sullivan, B., Gorbatchevsky, I., Pistilli, B. (2026). A randomized, open-label, phase 3 study of gedatolisib + fulvestrant ± palbociclib vs standard of care in HR+/HER2−/
                    <i>PIK3CA</i>
                    -mutant (MT) advanced breast cancer (VIKTORIA-1 Study 2).. Journal of Clinical Oncology. https://doi.org/10.1200/jco.2026.44.17_suppl.lba1008